Pluslife: Advancing Affordable and Accessible Solutions for TB Diagnosis and Elimination

Product Overview and Prcing

Pluslife provides tuberculosis (TB) diagnostic solutions that are reliable, affordable, fast, and simple, with the goal of expanding access of TB diagnosis in resource-limited settings. 

The Pluslife MiniDock TB Test provides a high-accuracy near-patient diagnostic layer—delivering fast results from simple specimens, close to the patient, with minimal training required, and serving as a supplementary diagnostic layer to existing TB diagnosis. 

In July 2025, Pluslife’s MiniDock MTB Test was included on the Global Fund’s List of TB diagnostic products under ERPD, confirming its eligibility for procurement under Global Fund-supported programs. See here.

The development of the MiniDock platform has been supported by the Gates Foundation (INV-074943), which enabled its readiness for use in LMICs by supporting technical validation and operational scale-up. Pluslife MiniDock MTB Test cards are priced at just $3.60 per test* (EXW China), The MiniDock Ultra device is priced at $155* (EXW China), and the Pluslife Thermolyse sample pretreatment device at $180* (EXW China), supporting practical, decentralized use in real-world settings. A two-year warranty is already included, with optional extension available. After-sales support is provided within two working days, in line with ISO 13485. 

We are willing to offer low profits TB testing to support public welfare initiatives aimed at tuberculosis prevention and control.
*Pricing is based on substantial procurement volumes and excludes taxes, shipping, and other related costs.

Access Commitments

This pricing is available to all qualified buyers in low- and middle-income countries (LMICs)—with a primary focus on national TB programs (NTPs) and healthcare providers across sectors.

The full list of eligible countries under this pricing initiative is provided in the Annex.

This pricing applies to all potential customers within eligible LMICs, including national TB programs, healthcare implementers, NGOs, and other public or private buyers. To ensure fairness, pricing is structured through a transparent and inclusive mechanism. As demand scales, further price reductions may be introduced for larger amount.

Clinical Performance and Validation

In head-to-head comparisons from the R2D2 study, the MiniDock MTB Test demonstrated comparable sensitivity (88.62% vs. 90.42%) and specificity (97.89% vs. 98.84%) to Xpert Ultra when using sputum samples. With tongue swab samples, the MiniDock MTB Test achieved significantly higher sensitivity than sputum smear microscopy (76.1% vs. 51.6%) while maintaining equally high specificity (99.5% vs. 99.8%). The tongue swab test exceeded WHO Target Product Profile (TPP) thresholds for non-sputum point-of-care TB diagnostics (≥75% sensitivity; ≥98% specificity), demonstrating potential for broader, accessible, and accurate TB diagnosis. ¹

Implementation and Use

In field usability testing, MiniDock was rated user-friendly, with functions viewed as well-integrated and little need for technical support. These findings reinforce suitability for decentralized use and non-sputum workflows, enabling rapid adoption with minimal training.

Future Outlook and Commitment

Pluslife remains committed to enabling high-performance TB testing in under-resourced settings through affordability, simplicity, and reliability. The company aims to support national TB programs and healthcare implementers in delivering timely, decentralized diagnosis while maintaining system sustainability.

 ¹Reference: R2D2 TB Network. Clinical Performance Study of MiniDock® MTB Test. Ad Hoc Clinical Data Analysis Report, 09 Jun 2025.

Annex: Eligible Countries

Low-Income Countries:

Lower-Middle Income Countries or High TB Burden Upper-Middle Income Countries:

*Presence on this list does not constitute a guarantee of funding or approval in a specific market. For up-to-date access terms and implementation status, please contact market@pluslife.com.